Abstract: Disclosed is a method for production of recombinant human iduronate 2-sulfatase (rhI2S) (the 26th to 550th amino acids of SEQ ID NO: 10) in a large scale, with a high purity, and mannose 6-phosphate residues. The method comprises the steps of (a) culturing rhI2S (the 26th to 550th amino acids of SEQ ID NO: 10)-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to cation-exchange column chromatography, (d) to dye affinity column chromatography, (e) to anion-exchange column chromatography, and (f) to a column chromatography employing as solid phase a material having affinity for phosphate group, and (g) to gel filtration column chromatography, in the order.
Abstract: This invention provides crystalline recombinant interferon (rSIFN-co (SEQ ID NO: 1)) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structural model of said interferon useful for drug screening and/or drug design, and mimetics of said interferon.
Abstract: The present invention relates to an improved process for the preparation of compound of Formula-II, which is an intermediate in the preparation of HMG-CoA reductase inhibitors. wherein X is hydrogen or hydroxy protecting group and R1 is carboxyl protecting group.
Type:
Grant
Filed:
May 28, 2014
Date of Patent:
March 1, 2016
Assignee:
Mylan Laboratories LTD
Inventors:
Michiel Christian Alexander Van Vliet, Willem Robert Klaas Schoevaart, Madhuresh Kumar Sethi, Sanjay Mahajan, Bhairaiah Mara
Abstract: The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight.
Abstract: Reaction solutions are disclosed herein comprising water, sucrose and a glucosyltransferase enzyme that synthesizes poly alpha-1,3-glucan. The glucosyltransferase enzyme can synthesize insoluble glucan polymer having at least 50% alpha-1,3 glycosidic linkages and a number average degree of polymerization of at least 100. Further disclosed are methods of using such glucosyltransferase enzymes to produce insoluble poly alpha-1,3-glucan.
Type:
Grant
Filed:
September 19, 2014
Date of Patent:
February 16, 2016
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
Mark S Payne, Yefim Brun, Hongxian He, Thomas Scholz
Abstract: Reaction solutions are disclosed herein comprising water, sucrose and a glucosyltransferase enzyme that synthesizes poly alpha-1,3-glucan. The glucosyltransferase enzyme can synthesize insoluble glucan polymer having at least 50% alpha-1,3 glycosidic linkages and a number average degree of polymerization of at least 100. Further disclosed are methods of using such glucosyltransferase enzymes to produce insoluble poly alpha-1,3-glucan.
Type:
Grant
Filed:
September 19, 2014
Date of Patent:
February 16, 2016
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
Mark S Payne, Yefim Brun, Hongxian He, Thomas Scholz
Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described.
Abstract: The present invention relates to a method for producing terpenes in fungi, wherein a terpene biosynthetic gene cluster having terpene biosynthetic genes and regulatory regions operably linked to said genes is activated. The invention relates also to a terpene biosynthetic gene duster and regulatory regions of such terpene biosynthetic gene cluster usable is production of terpenes, use of regulator for regulating the terpene production and use of Aspergillus nidulans FGSC A4 for producing terpenes. The method of invention provides higher yields of enriched terpene product without essential amount of side-products.
Type:
Grant
Filed:
November 14, 2011
Date of Patent:
January 19, 2016
Assignee:
Teknologian Tutkimuskeskus VTT Oy
Inventors:
Kirsi Bromann, Tina Nakari-Setala, Laura Ruohonen, Mervi Toivari, Merja Penttila
Abstract: Provided herein are polypeptides and polynucleotides encoding such polypeptides which have ketoisovalerate decarboxylase activity. Also provided are recombinant host cells comprising such polypeptides and polynucleotides and methods of use thereof.
Type:
Grant
Filed:
July 27, 2012
Date of Patent:
January 19, 2016
Assignee:
Butamax Advanced Biofuels LLC
Inventors:
Jessica McElvain, Daniel P O'Keefe, Brian James Paul, Mark S Payne, Steven Cary Rothman, Hongxian He
Abstract: Reaction solutions are disclosed herein comprising water, sucrose and a glucosyltransferase enzyme that synthesizes poly alpha-1,3-glucan. The glucosyltransferase enzyme can synthesize insoluble glucan polymer having at least 50% alpha-1,3 glycosidic linkages and a number average degree of polymerization of at least 100. Further disclosed are methods of using such glucosyltransferase enzymes to produce insoluble poly alpha-1,3-glucan.
Type:
Grant
Filed:
September 19, 2014
Date of Patent:
January 5, 2016
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
Mark S Payne, Yefim Brun, Hongxian He, Thomas Scholz
Abstract: Reaction solutions are disclosed herein comprising water, sucrose and a glucosyltransferase enzyme that synthesizes poly alpha-1,3-glucan. The glucosyltransferase enzyme can synthesize insoluble glucan polymer having at least 50% alpha-1,3 glycosidic linkages and a number average degree of polymerization of at least 100. Further disclosed are methods of using such glucosyltransferase enzymes to produce insoluble poly alpha-1,3-glucan.
Type:
Grant
Filed:
September 19, 2014
Date of Patent:
January 5, 2016
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
Mark S Payne, Yefim Brun, Hongxian He, Thomas Scholz
Abstract: Disclosed herein is a set of E. coli single-protein production (SPP) technologies with protein NMR (SPP-NMR) for (i) using isotope-enriched membrane proteins produced with the SPP system in screening detergent conditions suitable for purification and/or three-dimensional structure analysis without the requirement for protein purification, (ii) producing 2H, 13C, 15N enriched proteins suitable for high throughput and membrane protein NMR studies, and (iii) labeling with 13C—15N specific peptide bonds in proteins (referred to herein as SPP-PBL).
Type:
Grant
Filed:
May 24, 2013
Date of Patent:
January 5, 2016
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Gaetano T. Montelione, Masayori Inouye, Yuefeng Tang, Monica Roth, William Schneider
Abstract: The present invention relates to assays for monitoring activity of OGFOD1 activity, in particular, to assays for identifying modulators of OGFOD1 activity. The invention also relates to assays to monitor the prolyl hydroxylase activity of OGFOD1 on its substrate, the human ribosomal protein RPS23. The invention also enables the introduction of 3-hydroxyprolyl residues into peptides and proteins.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
January 5, 2016
Assignee:
ISIS INNOVATION LIMITED
Inventors:
Christopher Joseph Schofield, Alexander Wolf, Wei Ge, Armin Thalhammer, Christoph Loenarz, Peter John Ratcliffe, Matthew Edward Cockman
Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Type:
Grant
Filed:
May 7, 2014
Date of Patent:
December 15, 2015
Assignee:
Halozyme, Inc.
Inventors:
Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
Abstract: A method of biologically producing p-hydroxybenzoic acid, and a method for producing p-hydroxybenzoic acid from lignin through chemical and biological conversion.
Type:
Grant
Filed:
August 14, 2013
Date of Patent:
December 8, 2015
Assignee:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Won Jae Choi, Jong Won Byun, Jin Ho Ahn, Young Wan Ha, Joo-Hyun Seo
Abstract: A method for producing lignin derivatives from technical lignins by treatment with proteolytic enzymes (proteases), characterized in that the proteolytic treatment of the technical lignins significantly reduces the molar mass thereof.
Type:
Grant
Filed:
March 2, 2012
Date of Patent:
December 8, 2015
Assignee:
ANNIKKI GMBH
Inventors:
Ewald Srebotnik, Thomas Ters, Karin Fackler, Kurt Messner, Ortwin Ertl
Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase possessing endonuclease activity, wherein said PA subunit is from Influenza A 2009 pandemic H1N1 virus or is a variant thereof. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
Type:
Grant
Filed:
March 15, 2011
Date of Patent:
November 10, 2015
Assignee:
European Molecular Biology Laboratory
Inventors:
Stephen Cusack, Eva Kowalinski, Chloe Zubieta
Abstract: The present invention provides a new fungal production system comprising a fungal host strain of Chrysosporium lucknowense wherein the endogenous cellulase secretion is less than 20% of the endogenous cellulase secretion of Chrysosporium lucknowense strain UV 18-25. Preferably, also the secretion of endogenous protease, endogenous ?-glucanase and endogenous cellobiohydrolase is less than 20% of the secretion of Chrysosporium lucknowense strain UV 18-25. Furthermore, fungal host strains are provided wherein several genes have been disrupted. According to another aspect of the invention a method for homologous and/or heterologous production of a pure protein with a purity of higher than 75%, comprising expressing a gene encoding said protein in the strains according to the invention have been described. Furthermore, a method for production of artificial protein mixes comprising expressing a gene encoding each of said proteins in a strain according to the invention have been disclosed.
Type:
Grant
Filed:
March 16, 2010
Date of Patent:
November 3, 2015
Assignee:
DYADIC NEDERLAND B.V.
Inventors:
Peter J. Punt, Richard Paul Burlingame, Christine M. Pynnonen, Phillip T. Olson, Jan Wery, Johannes Heinrich Visser, Mark A. Emalfarb, Jacob Visser, Jan Cornelis Verdoes, Jacoba Verdoes
Abstract: Provided are R-praziquantel preparation methods, which utilize the characteristics of biological enzyme of strong stereoselectivity, site-selectivity, and regioselectivity, of high resolution efficiency, of mild reaction conditions, and of simple operations to catalyze the hydrolysis of a certain enantiomer in a chemically synthesized racemate or a derivative, thus acquiring a mixture of reacted and unreacted optical isomers. R-praziquantel prepared by the method can have a purity of 98% or more.